Drugs / SAR443579
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06508489 | Aug 2024 → Aug 2025 | acute myeloid leukemia | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05086315 | Dec 2021 → Jun 2025 | CD4+/CD56+ hematodermic neoplasm, acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Sanofi | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2024-06-17 | Innate Pharma | Results Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial innate-pharma.com ↗
We are pleased to see that SAR’579 continues to show promising and durable clinical efficacy along with a favorable safety profile. |
| 2023-12-11 | Innate Pharma | Results Innate Pharma shares efficacy and safety Phase 1 /2 results of NK Cell Engager SAR443579 / IPH6101 developed by Sanofi at ASH 2023 innate-pharma.com ↗
SAR443579 induced clinical benefit in patients with R/R AML with 5 complete remissions (4 CR / 1 CRi) achieved at 1 mg/kg |
| 2023-11-03 | Innate Pharma | Results Innate Pharma announces new clinical data for lacutamab and SAR443579/IPH6101 at ASH 2023 innate-pharma.com ↗
Presentation on SAR443579 / IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123; SAR443579 / IPH6101 is ANKET® platform lead asset and under development by partner Sanofi, which demonstrated clinical remissions |
| 2023-05-26 | Innate Pharma | Results Innate Pharma highlights Phase 1/2 dose escalation safety and preliminary efficacy of Sanofi developed first NK Cell Engager SAR'579 / IPH6101 in R/R AML innate-pharma.com ↗
Preliminary data published show SAR’579 was well tolerated and induced 3 complete responses in the 8 patients at 1 mg/kg as highest dose |
| 2023-01-16 | Innate Pharma | Results Innate Pharma announces publication of preclinical data with a trifunctional NK cell engager in acute myeloid leukemia in Nature Biotechnology innate-pharma.com ↗
In vivo, its antitumor activity in a mouse tumor model exceeds that of the comparator anti-CD123 antibody. |
| 2021-11-16 | Innate Pharma | Results Innate Pharma Third Quarter 2021 Report innate-pharma.com ↗
IPH6101/SAR443579 demonstrated potent antitumor activity against AML cell lines and primary AML blasts, including those resistant to ADCC by a comparator anti-CD123 antibody. |
| 2021-11-12 | Innate Pharma | Results Innate Pharma highlights new NK cell engager data with partner Sanofi at SITC annual meeting innate-pharma.com ↗
In pre-clinical studies, IPH6101/SAR443579 demonstrated potent antitumor activity against AML cell lines, including those resistant to ADCC by a comparator anti-CD123 antibody. |
All press releases naming this drug 10 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR443579 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06508489 ↗ |
| Modality | Other / unclassified | “Natural Killer Cell Engager (NKCE)” NCT06508489 ↗ |
| Route | Intravenous | “by IV infusion” NCT05086315 ↗ |